Advertisement
UK markets closed
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     
  • CRUDE OIL

    78.50
    +0.02 (+0.03%)
     
  • GOLD FUTURES

    2,321.20
    -10.00 (-0.43%)
     
  • DOW

    38,884.33
    +32.06 (+0.08%)
     
  • Bitcoin GBP

    50,376.12
    -150.66 (-0.30%)
     
  • CMC Crypto 200

    1,309.27
    -55.85 (-4.09%)
     
  • NASDAQ Composite

    16,330.94
    -18.30 (-0.11%)
     
  • UK FTSE All Share

    4,522.99
    +53.90 (+1.21%)
     

Supernus drug meets main goal of study in adults with ADHD

(Reuters) - Supernus Pharmaceuticals Inc said on Tuesday its experimental drug for attention deficit hyperactivity disorder (ADHD) met the main goal of a late-stage study test in adults.

The drug, SPN-812, is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in children 6 to 17 years of age.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Chris Reese)